NCT07518277 (sirolimus) is a NA clinical trial of Glucocorticoids in Autoimmune Hemolytic Anemia (AIHA), sponsored by Chen Miao.

Who is sponsoring NCT07518277?

NCT07518277 is sponsored by Chen Miao.

What drugs are being tested in NCT07518277?

Interventions in NCT07518277: Glucocorticoids.

What condition does NCT07518277 study?

NCT07518277 studies Autoimmune Hemolytic Anemia (AIHA).

Is NCT07518277 still recruiting?

NCT07518277 is currently not yet recruiting. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT07518277: sirolimus

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia

Not yet recruiting NA Last updated 8 April 2026

What this trial tests

NA trial testing Glucocorticoids in Autoimmune Hemolytic Anemia (AIHA) in 216 participants. Not yet recruiting.

Timeline

1 April 2026

Primary endpoint
1 April 2028

1 April 2028

Quick facts

Lead sponsor	Chen Miao
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	216
Start date	1 April 2026
Primary completion	1 April 2028
Estimated completion	1 April 2028
Sites	1 location across China

Drugs / interventions tested

Glucocorticoids — full drug profile →

Conditions studied

Autoimmune Hemolytic Anemia (AIHA) — all drugs for Autoimmune Hemolytic Anemia (AIHA) →

Sponsor

Chen Miao

Who can join

Adults 18 to 75, any sex, with Autoimmune Hemolytic Anemia (AIHA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multicenter, randomized controlled trial. A total of 216 adult patients with newly diagnosed wAIHA were planned to be included and randomly assigned in a 1:1 ratio to the experimental group (glucocorticoid combined with sirolimus) or the control group (glucocorticoid monotherapy). The initial dose of sirolimus in the experimental group was 1mg/d, adjusted according to the blood drug concentration. The target concentration was 4-12ng/mL, and the treatment course was 6 months. Both groups of hormones were gradually reduced according to the standard protocol. All patients were followed up for 24 months, and the differences between the two groups at endpoints such as the hormone-free sustained response rate at the 12th month were compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Glucocorticoids

Trials testing the same drug.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07542314 — Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a · Phase 4 · not yet recruiting
NCT06663943 — A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. · Phase 1, PHASE2 · not yet recruiting
NCT07152366 — Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the A · Phase 4 · recruiting
NCT07152340 — The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO · Phase 4 · recruiting

Other recruiting trials for Autoimmune Hemolytic Anemia (AIHA)

Currently open trials in the same condition.

NCT07205315 — A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07518277 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chen Miao
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07518277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing